Victory over Adamu Single Resistance, again over Abassup, Abbvie continued to build on.

Recently, Abbott released new data of select choice, a phase III trial of oral Jak1 inhibitor rinvoq (upadacitinib) in the treatment of rheumatoid arthritis.the select choice trial is a multicenter, randomized, double-blind, III clinical trial designed to evaluate the efficacy and safety of upatinib in the treatment of rheumatoid arthritis.select choice is the sixth and final phase III study of the select-ra clinical trial.this study was conducted in adult patients with moderate to severe rheumatoid arthritis (RA) who were previously under or intolerant to biological disease modified antirheumatic drugs (bdmar).the main end point of the study was that rinvoq? And orencia? (? Abaacept, intravenous infusion) of Bristol Myers Squibb had non inferiority in terms of baseline changes in disease activity score 28 C-reactive protein (das28-crp) at week 12 of treatment.in addition, several key secondary endpoints were achieved: rinvoq? Was superior to orencia? In terms of changes in das28-crp from baseline at week 12 and clinical remission (measured by das28-crp < 2.6) at week 12.the results of the select choice trial, which is a selective and reversible JAK inhibitor developed by Aberdeen, was initially launched in the United States in August 2019 for the treatment of adult patients with moderate to severe rheumatoid arthritis who are under or intolerant to methotrexate.in addition, the treatment of psoriatic arthritis, Crohn's disease, atopic dermatitis, giant cell arteritis and ulcerative colitis is under clinical phase III study, the treatment of ankylosing spondylitis and systemic lupus erythematosus is under clinical phase II study, and the treatment of juvenile rheumatoid arthritis is under clinical phase I study.as early as March this year, Abbott announced that upatinib was superior to Humira in the treatment of psoriatic arthritis, based on the positive results of a select PSA 1 phase III clinical trial.select PSA 1 is a multicenter, randomized, double-blind, parallel group, active and placebo-controlled clinical phase 3 study to evaluate the safety and efficacy of rinvoq? In adult patients with active psoriatic arthritis who are underresponsive to at least one abiotic DMARD, compared with placebo and adalimumab.the results showed that compared with adalimumab, the efficacy of rinvoq? 15 mg and 30 mg was non inferiority, and the 30 mg group showed more advantages.Michael Severino, MD, vice president and President of Aberdeen, said: "despite the great progress in the treatment of rheumatoid arthritis, about 70% of patients still can not achieve clinical remission through the existing mature treatment.we are satisfied with the results as it further enriches the evidence that rinvoq? May provide a better opportunity for clinical remission in more adult patients with rheumatoid arthritis, including those who have previously failed to receive biological agents.”